Geneva, July 20 -- International Clinical Trials Registry received information related to the study (ISRCTN11391276) titled 'Oral anticoagulation (apixaban) to prevent early liver disease worsening' on July 9.
Study Type: Interventional
Study Design:
Allocation: Randomized controlled trial
Masking: Blinded (masking used)
Control: Placebo
Assignment: Parallel
Purpose: Prophylaxis
Primary Sponsor: University College London
Condition:
Liver cirrhosis secondary to alcohol, with or without associated metabolic risk factors, i.e. Alcohol Related Liver Disease (ARLD) or metabolic dysfunction-associated steatotic liver disease, where there has been a significant history of alcohol consumption (MetALD)
Digestive System
Intervention:
1. A...